Simple, transparent
pay-per-compound pricing
No subscriptions. No seat licences. Pay only for the compounds you screen — with all 50+ ADMET endpoints and QMRF documentation included in every purchase.
No credit card required. Start screening immediately.
Pay-per-compound packages
All packages include the full endpoint set and QMRF documentation.
Everything included in every purchase
One price, the complete picture.
Included
Not included (add-ons)
Written interpretation by a medicinal chemist or toxicologist. Includes mechanistic narrative, read-across commentary, and regulatory-ready language suitable for IND/NDA dossiers.
Request expert reportFree trial vs. full purchase
The free trial lets you experience the platform before committing.
| Feature | Free Trial | Full Purchase |
|---|---|---|
| Available Endpoints | 5 | 50+ |
| Compound count | 2 | Unlimited |
| QMRF documentation | ||
| OECD-compliant predictions | ||
| Read-across analysis | ||
| Risk Score ranking | ||
| Signing an NDA | ||
| PDF report | ||
| Regulatory use |
Screening hundreds of compounds?
Custom volume pricing, NDA agreements, and dedicated data handling for large-scale screening campaigns. Enterprise packages are available for pharma teams, CROs, and research institutions.
We typically respond within 1 business day.
“A failed in vivo safety study costs $500k–$2M. Catching that compound in silico at $150 is not a cost — it’s an insurance policy.”